Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial.
K BorowczykJ PiechockaR GłowackiI DharØ MidtunG S TellP M UelandO NygårdHieronim JakubowskiPublished in: Journal of internal medicine (2018)
Hcy-thiolactone/creatinine ratio is a novel AMI risk predictor in patients with suspected CAD, independent of traditional risk factors and tHcy, but modified by vitamin B6 catabolism. These findings lend a support to the hypothesis that Hcy-thiolactone is mechanistically involved in cardiovascular disease.
Keyphrases
- acute myocardial infarction
- coronary artery disease
- cardiovascular disease
- risk factors
- end stage renal disease
- percutaneous coronary intervention
- ejection fraction
- chronic kidney disease
- newly diagnosed
- study protocol
- peritoneal dialysis
- cardiovascular events
- clinical trial
- prognostic factors
- type diabetes
- randomized controlled trial
- metabolic syndrome
- heart failure
- acute coronary syndrome
- uric acid
- patient reported outcomes